Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Ab&B Bio-Tech CO., LTD. JS Class H ( (HK:2627) ).
Ab&B Bio-Tech CO., LTD. JS announced that its Investigational New Drug application for a self-developed Recombinant RSV vaccine (CHO cell) (Adjuvant) has been approved by both the China Center for Drug Evaluation and the U.S. Food and Drug Administration. This vaccine, targeting the highly contagious Respiratory Syncytial Virus, shows promising preclinical results with higher expression levels, better thermal stability, and superior immunogenicity compared to existing vaccines. The approval marks a significant step forward for the company in addressing a major health concern, potentially enhancing its market position and offering a new preventive solution for RSV infections.
More about Ab&B Bio-Tech CO., LTD. JS Class H
Ab&B Bio-Tech CO., LTD. JS is a China-based vaccine company focused on the research, development, manufacturing, and commercialization of innovative and traditional vaccines using new technical methods. The company aims to replace traditional and imported vaccines in China and expand its presence in international markets. Its product range includes the quadrivalent subunit influenza vaccine and lyophilized human rabies vaccine candidate, among others.
Average Trading Volume: 4,673,565
Find detailed analytics on 2627 stock on TipRanks’ Stock Analysis page.